Anatara Lifesciences Ltd logo

Anatara Lifesciences Ltd (ANR)

Market Open
CXA CXA
- Market Cap
- P/E Ratio
- Div Yield
75,158 Volume
0 Eps
Want to track ANR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ANR is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on CXA (AUD).

Anatara Lifesciences Ltd (ANR) FAQ

On which exchange is it traded?

Anatara Lifesciences Ltd is listed on CXA.

What is its stock symbol?

The ticker symbol is ANR.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Anatara Lifesciences Ltd ever had a stock split?

No, there has never been a stock split.

Anatara Lifesciences Ltd Profile

Biotechnology Industry
Healthcare Sector
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS CEO
CXA Exchange
- ISIN
Australia Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Anatara Lifesciences Ltd is an innovative company focused on the development and commercialization of novel solutions aimed at addressing gastrointestinal diseases in both animals and humans. Based in Adelaide, Australia, and established in 2010, the company pioneers in creating evidence-based formulations that tackle the root causes of these conditions. Through rigorous research and development efforts, Anatara Lifesciences strives to bring to market products that offer significant benefits over current treatment options, highlighting their commitment to improving health outcomes using natural and scientifically validated ingredients.

Products and Services

  • Gastrointestinal ReProgramming (G.I.R.)

    This proprietary formulation combines the enzyme bromelain with other evidence-based ingredients to combat the underlying factors responsible for various human gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). G.I.R. is designed to offer a comprehensive approach to gastrointestinal health, leveraging the natural therapeutic properties of its constituents.

  • Detach

    An innovative non-antibiotic biotherapeutic product designed to prevent and treat diarrheal diseases in piglets. Detach works by reducing the attachment of pathogenic bacteria to the intestines, thereby minimizing the incidence and severity of diarrheal conditions. This product aims to improve the health and welfare of livestock while addressing concerns about antibiotic resistance.

  • BONIFF

    A tailored formulation added to dry feed for piglets post-weaning, BONIFF is engineered to enhance the digestive health and welfare of piglets during this critical period. Its specific composition supports the gut health of young pigs, aiding in the smooth transition from milk to solid food and fostering optimal growth and development.

  • ANR-pf

    ANR-pf is a proprietary formulation designed for use in poultry, administered through water. This product addresses gastrointestinal issues common in poultry, promoting better health, enhanced growth rates, and overall productivity. By improving gut health, ANR-pf contributes to the efficiency and sustainability of poultry farming operations.

Contact Information

Address: 81 Flinders Street
Phone: 61 4 3802 7172